What do systematic reviews say?

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes

  Minimum 2 weeks
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes

  Minimum 2 weeks
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes
  No data available (no included studies)
  0 studies
  No studies found

Amiodarone vs placebo or no treatment

Amiodarone may leads to lower sudden cardiac death compared with placebo or no treatment (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.76 [0.66, 0.88]
  17 studies · 8383 participants
  Low

Amiodarone vs other antiarrhythmics

Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 1.03 [0.75, 1.42]
  5 studies · 898 participants
  Low

Amiodarone vs beta‐blocker

It is very uncertain whether amiodarone changes sudden cardiac death compared with beta blockers (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.84 [0.55, 1.27]
  1 study · 189 participants
  Very low

Amiodarone vs beta‐blocker

It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.7, 1.32]
  1 study · 189 participants
  Very low

Amiodarone vs sotalol

It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 2.87 [0.32, 25.55]
  1 study · 45 participants
  Very low

Amiodarone vs sotalol

It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 1.08 [0.41, 2.83]
  2 studies · 104 participants
  Very low

Amiodarone vs placebo or no treatment

Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.78, 1]
  17 studies · 8383 participants
  Low

Amiodarone vs beta‐blocker

Amiodarone showed no clear difference in sudden cardiac death compared with beta blockers (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.37 [0.11, 1.22]
  2 studies · 342 participants
  Low

Amiodarone vs beta‐blocker

Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.27 [0.1, 0.75]
  2 studies · 342 participants
  Low

Amiodarone vs other antiarrhythmics

Amiodarone showed no clear difference in sudden cardiac death compared with other antiarrhythmics (moderate certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.44 [0.19, 1]
  3 studies · 540 participants
  Moderate

Amiodarone vs other antiarrhythmics

Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.37 [0.18, 0.76]
  3 studies · 540 participants
  Moderate

Amiodarone vs placebo or no treatment

It is very uncertain whether amiodarone changes sudden cardiac death compared with placebo or no treatment (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 4.32 [0.87, 21.49]
  2 studies · 440 participants
  Very low

Amiodarone vs placebo or no treatment

It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 3.05 [1.33, 7.01]
  2 studies · 440 participants
  Very low